High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate Cancer.

BACKGROUND

The effect of lipoprotein(a) (Lp(a)) on prostate cancer (PCa) is unclear. The aim of this study was to investigate the association between serum Lp(a) levels and clinicopathological features in patients with PCa.

METHODS

A total of 376 consecutive pathologically diagnosed PCa patients were enrolled and were classified as a low-intermediate-risk group or a high-risk group. The association of Lp(a) and the other lipid parameters including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), TC/HDL-C, LDL-C/HDL-C, and remnant cholesterol (RC) with clinicopathological parameters was tested by univariate and multivariate logistic regression analyses.

RESULTS

The high-risk PCa patients tended to have higher Lp(a) levels ( = 0.022) while there was no significant difference regarding the other lipid parameters ( > 0.05) compared to low-intermediate-risk counterparts. Patients with PSA ≥ 100 ng/ml had significantly higher Lp(a) levels than subjects with PSA < 100 ng/ml ( = 0.002). Univariate logistic regression analyses revealed that high Lp(a) levels were correlated with high-risk PCa (Q4 vs. Q1, HR = 2.687, 95% CI: 1.113-6.491, = 0.028), while the other lipid parameters were not correlated with high-risk PCa. In the stepwise multivariate regression analysis, the association between Lp(a) levels and high-risk PCa remained significant (Q4 vs. Q1, HR = 2.890, 95% CI: 1.148-7.274, = 0.024) after adjusting for confounding factors including age, body mass index, hypertension, diabetes, coronary artery disease, and lipid-lowering drugs.

CONCLUSIONS

This is the first study showing the positive association between high Lp(a) and adverse clinicopathological features of PCa. PCa patients with high Lp(a) tends to be more aggressive and should receive more attention in clinical practice.